DCTH — Delcath Systems, Inc.
Is DCTH overbought or oversold? Here is the current MarketMoodz read.
Delcath Systems, Inc. (DCTH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $19.37. The rating moved from Overbought to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$19.37
- Last changeMoved from Overbought to Oversold on November 16, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Delcath Systems, Inc. (DCTH) is a niche interventional oncology company with a focused hepatic infusion platform and limited public information available in the provided dataset. Sector flows toward specialty infusion and biopharma services are a constructive background, and consolidation dynamics in healthcare could offer potential strategic outcomes. However, execution uncertainty, likely constrained cash runway, reimbursement and regulatory risks, and typical small‑cap liquidity/volatility mean near-term movement is expected to be headline-driven and choppy. Monitor clinical/regulatory milestones, partnership or M&A activity, and any updated financial disclosures for clearer directional signals.
Key factors
- Small-cap specialty interventional oncology device company with a focused hepatic infusion therapy platform and limited commercial scale
- Market environment showing selective support for specialty care, infusion and biopharma services which could sustain prescription and procedure flows benefiting niche infusion technology providers
- Historical regulatory and commercial execution challenges for similarly positioned companies increase uncertainty around near-term revenue growth and adoption
- Potential M&A or partnership interest from larger specialty pharma/medtech consolidators given sector consolidation trends, which could be a medium-term catalyst
- No recent EDGAR or social sentiment signals available in the provided data, increasing informational opacity
- Current macro / market tone is risk-on but consolidated, offering limited immediate directional conviction for small, speculative names
Risks
- Limited available public financial disclosures in the provided dataset — cash runway and revenue visibility may be constrained, increasing dilution risk
- Clinical or regulatory setbacks for the therapy/delivery platform could materially reduce valuation and commercial prospects
- Reimbursement uncertainty and payer scrutiny (heightened regulatory focus on program integrity and cost controls) could suppress adoption or pricing
- Competitive pressure from other hepatic oncology approaches, systemic therapies, or evolving standard-of-care could limit addressable market
- Low liquidity and high share volatility common to micro/small-cap biotech/medtech stocks can amplify downside on adverse news
- Absence of clear near-term commercial milestones or material newsflow increases probability of prolonged sideways trading or episodic sell-offs
See today's live rating, score and targets
Members see the live hourly rating for DCTH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.